OBJECTIVES: Pancreatic endocrine tumors (PETs) are infrequent, which makes large experiences unlikely. Our aim was to describe a large single-center experience with PETs and the use of endoscopic ultrasound (EUS) and a cancer staging system (TNM). METHODS: This study involves a retrospective analysis of 86 patients (44 men; age, 58 +/- 14 years) who underwent EUS-fine needle aspiration (EUS-FNA). Immunohistochemistry was used. Lesions were classified as recommended by TNM classification. RESULTS: Typical EUS features were well-demarcated, hypoechoic, solid, homogeneous lesions. Ninety percent had the diagnosis obtained by EUS-FNA. Twelve PETs (14%) were functioning, 8 (9.3%) were cystic, and 14 (16%) were 10 mm or smaller. Nonfunctional PETs and larger lesions were more advanced. The TNM stage was I in 24, II in 10, III in 18, and IV in 34 patients. Sixteen patients (27%) died, and 30 patients (52%) had progression/recurrence during the follow-up (34 +/- 27 months). TNM stage and surgery with curative intent were related to progression. The overall 5-year survival was 60%. The mean survival time was 94 +/- 12 months for stage I, 52 +/- 12 months for stage III, and 54 +/- 7 months for stage IV (P = 0.06). CONCLUSIONS: Nonfunctional PETs were more common and advanced. The EUS-FNA has a high accuracy for diagnosing PETs. Progression and poorer survival were associated with TNM stage.
OBJECTIVES:Pancreatic endocrine tumors (PETs) are infrequent, which makes large experiences unlikely. Our aim was to describe a large single-center experience with PETs and the use of endoscopic ultrasound (EUS) and a cancer staging system (TNM). METHODS: This study involves a retrospective analysis of 86 patients (44 men; age, 58 +/- 14 years) who underwent EUS-fine needle aspiration (EUS-FNA). Immunohistochemistry was used. Lesions were classified as recommended by TNM classification. RESULTS: Typical EUS features were well-demarcated, hypoechoic, solid, homogeneous lesions. Ninety percent had the diagnosis obtained by EUS-FNA. Twelve PETs (14%) were functioning, 8 (9.3%) were cystic, and 14 (16%) were 10 mm or smaller. Nonfunctional PETs and larger lesions were more advanced. The TNM stage was I in 24, II in 10, III in 18, and IV in 34 patients. Sixteen patients (27%) died, and 30 patients (52%) had progression/recurrence during the follow-up (34 +/- 27 months). TNM stage and surgery with curative intent were related to progression. The overall 5-year survival was 60%. The mean survival time was 94 +/- 12 months for stage I, 52 +/- 12 months for stage III, and 54 +/- 7 months for stage IV (P = 0.06). CONCLUSIONS: Nonfunctional PETs were more common and advanced. The EUS-FNA has a high accuracy for diagnosing PETs. Progression and poorer survival were associated with TNM stage.
Authors: Muslim Atiq; Manoop S Bhutani; Mehmet Bektas; Jeffrey E Lee; Yun Gong; Eric P Tamm; Chintan P Shah; William A Ross; James Yao; Gottumukkala S Raju; Xuemei Wang; Jeffrey H Lee Journal: Dig Dis Sci Date: 2011-10-01 Impact factor: 3.199
Authors: Vegard Tjomsland; Per Sandström; Anna Spångeus; Davorka Messmer; Johan Emilsson; Ursula Falkmer; Sture Falkmer; Karl-Eric Magnusson; Kurt Borch; Marie Larsson Journal: BMC Cancer Date: 2010-03-09 Impact factor: 4.430
Authors: Robert T Jensen; Guillaume Cadiot; Maria L Brandi; Wouter W de Herder; Gregory Kaltsas; Paul Komminoth; Jean-Yves Scoazec; Ramon Salazar; Alain Sauvanet; Reza Kianmanesh Journal: Neuroendocrinology Date: 2012-02-15 Impact factor: 4.914
Authors: Jane Bernstein; Berrin Ustun; Ahmed Alomari; Fang Bao; Harry R Aslanian; Uzma Siddiqui; David Chhieng; Guoping Cai Journal: Cytojournal Date: 2013-05-29 Impact factor: 2.091